Note: Funding Information: J.E. is supported by the DZHK (German Centre for Cardiovascular Research) and by Fondation Leducq (18CVD02, PlaqOmics). S.W.vd.L is funded through grants from the Netherlands CardioVascular Research Initiative of the Netherlands Heart Foundation [CVON 2011/B019 and CVON 2017-20: Generating the best evidence-based pharmaceutical targets for atherosclerosis (GENIUS I&II)] and the Horizon 2020 TO_AITION (grant no. 848146, H2020-SC1-2019-Two-Stage-RTD). We are grateful for the support of the ERA-CVD program ‘druggable-MI-targets’ (grant no. 01KL1802).